Faculty & Research
Publications
Publications
  • October 1992 (Revised November 1997)
  • Case
  • HBS Case Collection

ImmuLogic Pharmaceutical Corporation (A): March 1991

By: Josh Lerner
  • Format:Print
  • | Pages:20
ShareBar

Abstract

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems of valuation are highlighted. The challenges posed by "windows" for public offerings are considered.

Keywords

Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Biotechnology Industry; Pharmaceutical Industry

Citation

Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (A): March 1991." Harvard Business School Case 293-066, October 1992. (Revised November 1997.)

About The Author

Josh Lerner

Entrepreneurial Management
More Publications

More from the Author